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Abstract
Cyclotides are plant proteins with exceptional stability owing to the presence of a cyclic backbone and three
disulfide bonds arranged in a cystine knot motif. Accordingly, they have been proposed as templates to stabilize
bioactive epitopes in drug-design applications. The two main subfamilies, referred to as the Mo¨bius and bracelet
cyclotides, require dramatically different in vitro folding conditions to achieve the native fold. To determine the
underlying elements that influence cyclotide folding, we examined the in vitro folding of a suite of hybrid
cyclotides based on combination of the Mo¨bius cyclotide kalata B1 and the bracelet cyclotide cycloviolacin O1.
The folding pathways of the two cyclotide subfamilies were found to be different and influenced by specific
residues within intercysteine loops 2 and 6. Two changes in these loops, a substitution in loop 2 and an addition
in loop 6, enabled the folding of a cycloviolacin O1 analogue under conditions in which folding does not occur
in vitro for the native peptide. A key intermediate contains a native-like hairpin structure that appears to be a
nucleation locus early in the folding process. Overall, these mechanistic findings on the folding of cyclotides are
potentially valuable for the design of new drug leads. Antioxid. Redox Signal. 11, 971–980.
Introduction
The cyclotides (12) are the largest family of circularproteins currently known and contain a unique structural
motif referred to as the cyclic cystine knot (CCK). This ex-
tremely stable motif is formed by the combination of a cyclic
backbone and three conserved disulfide bonds arranged in a
knotted topology. Several backbone loops project from the
stable molecular core of cyclotides, as illustrated in Fig. 1. The
primary function of cyclotides is thought to be as plant de-
fense agents based on their potent insecticidal activity against
the larvae of several Helicoverpa species (4, 25, 31, 32). How-
ever, cyclotides are functionally versatile and display a range
of other bioactivities, including uterotonic (22–24), anti-HIV
(27, 28), cytotoxic (35, 44), hemolytic (17, 30, 42, 46), antimi-
crobial (46), antifouling (21), nematicidal (10), and mollusci-
cidal (38) activities. More than 100 cyclotides have been
characterized (36, 47), with hypervariable sequences occu-
pying the backbone loops. The combined features of excep-
tional stability, functional diversity, and an ability to tolerate a
wide range of sequences make cyclotides potentially useful as
molecular engineering templates onto which bioactive epi-
topes can be grafted and thereby stabilized (11, 14). Other
peptides, such as knottins (8) and BPTI (39), have been used as
scaffolds to graft nonnative activities, highlighting the po-
tential of peptide scaffolds in drug design.
Two main cyclotide subfamilies have been defined: the
Mo¨bius and bracelet subfamilies, based on the geometry of an
X-Pro peptide bond in the circular backbone (12). In Mo¨bius
cyclotides a cis-peptide bond in loop 5 results in a conceptual
180-degree twist in the backbone, as illustrated in Fig. 1. In
contrast, bracelet cyclotides lack the corresponding proline
residue and have a bracelet (all-trans) topology. Loops 1 and 4
of cyclotides form part of the cystine knot and are highly
conserved across the two subfamilies. Despite some degree of
sequence similarity within subfamilies, loops 2, 3, 5, and 6
vary in size and sequence across different cyclotides, as
shown in Fig. 1. Based on the presence of a CCK topology (20),
the two peptidesMomordica cochinchinensis trypsin inhibitor I
(MCoTI-I) and MCoTI-II, discovered in 2000 (29), constitute a
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third cyclotide subfamily known as the trypsin-inhibitor cy-
clotides (13). These peptides are also referred to as ‘‘cyclic
knottins,’’ as they show high sequence similarity to linear
trypsin inhibitors found within certain squash plants (7).
Mo¨bius cyclotides can be efficiently synthesized by first
assembling linear precursor sequences via solid-phase syn-
thesis and then using a thioester-mediated strategy to gen-
erate the cyclic product (17, 46). Under alkaline folding
conditions, cyclization and oxidation of the cysteines occur in
a single step to give the natively folded conformation in high
yields. Unlike conventional proteins that generally have hy-
drophobic residues in the protein core, native cyclotides have
many of their hydrophobic residues exposed on themolecular
surface. Inclusion of the hydrophobic agent isopropanol in the
folding medium significantly increases the folding efficiency
of the prototypicalMo¨bius cyclotide kalata B1, presumably by
stabilizing the patch of hydrophobic residues that is exposed
to solvent on folding (17).
Despite the high yields obtained for folding of Mo¨bius cy-
clotides, the folding of bracelet cyclotides has been problem-
atic. In early studies of cyclotide synthesis, Tam et al. (45)
reported that synthetic bracelet cyclotides require complex
folding conditions and selective cysteine protection followed
by directed oxidative folding to attain the native conforma-
tion. Recently, successful in vitro folding conditions for the
bracelet cyclotide cycloviolacin O2 were reported that en-
abled folding yields up to *50% (34). The optimal folding
conditions were established after many attempts at folding
under a wide range of conditions, including different buffer
systems, temperatures, and metal ions, were unfruitful (1),
indicating that folding of bracelet cyclotides is not as robust as
that of Mo¨bius cyclotides.
Grafting of bioactive sequences into cyclotide frameworks
to derive biologically stable analogues has been proposed as a
potential therapeutic application of cyclotides (11, 14). How-
ever, such applications have so far not been extended to
members of the bracelet subfamily owing to the difficulties
associated with their folding. More than 60% of the cyclotides
discovered to date are bracelet cyclotides (43), and several
NMR studies have confirmed that bracelet scaffolds possess
naturally stable conformations (5, 32, 33, 37, 40), indicating
that overall, the bracelet subfamily contains a large number of
potential scaffolds available for protein-engineering applica-
tions. To optimize the range of cyclotide scaffolds used in
drug-design applications, an understanding of the funda-
mental elements that dictate the in vitro folding of bracelet
cyclotides is essential.
We examine the key structural features that influence the in
vitro folding of the two main cyclotide subfamilies. To deter-
mine which backbone loops or key residues in cyclotides
influence in vitro folding, we designed a suite of Mo¨bius-
bracelet hybrid cyclotides based on the prototypical Mo¨bius
and bracelet cyclotides kalata B1 and cycloviolacin O1, re-
spectively. Our study indicates the structural elements that
hinder the folding of bracelet cyclotides under conditions that
are effective for Mo¨bius counterparts and provides a new
approach to folding of bracelet cyclotides by introducing
simple modifications to the sequence.
Materials and Methods
Synthesis of Mo¨bius-bracelet hybrids and native
cycloviolacin O1
A series of bracelet-Mo¨bius hybrids (hybrids 1–15)
and native cycloviolacin O1 were assembled using Boc
(t-butoxycarbonyl) chemistry (41) and purified by using
methods previously described (9). In brief, peptides were as-
sembled on a PAM (phenylacetamidomethyl) resin (Applied
Biosystems, Foster City, CA) on a 0.3-mmol scale and were
designed to contain a C-terminal thioester linker and an N-
terminal cysteine (18). RP-HPLC was used to purify the
peptides, and the fractions containing the correct mass de-
tected by ESI-MS were freeze dried and used for the oxidative
folding study.
Oxidative folding of hybrids. The hybrid peptides
(0.1mg=ml) were oxidized by using an array of nine small-
scale in vitro folding oxidation buffers containing different
proportions of 0.1M ammonium bicarbonate (pH 8.5), iso-
propanol, and glutathione as shown in Table 1. The oxidative
folding condition that gave a prominent peak in high yield for
each peptide was repeated in large scale (total volume of
100ml) for 24h, and the folded peptide was purified on a
semipreparative column by using a linear gradient of solvent
A (0.1% aqueous trifluoroacetic acid) and B (0.05% tri-
fluoroacetic acid in 90% acetonitrile=10% water). Fractions
FIG. 1. Distinctive structural features of the Mo¨bius and
bracelet cyclotide subfamilies. A comparison of the three-
dimensional structures of the prototypical Mo¨bius cyclotide
kalata B1 (left) and bracelet cyclotide cycloviolacin O1 (right)
is shown; the three conserved disulfides forming the cystine
knot are depicted in a ball-and-stick model, and the anti-
parallel b sheets are shown with flat arrows. The schematic
diagram shows the Mo¨bius and bracelet topologies; bracelet
scaffold contains the conceptual twist between the Trp and
Pro residue in loop 5. An alignment of sequences for repre-
sentative members of each subfamily is shown at the bottom
of the figure.
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containing the correct mass were identified by ESI-MS and
further analyzed with RP-HPLC for purity. Pure fractions
(>95% purity) were freeze dried and examinedwith 1H-NMR.
NMR experiments. Samples for 1H-NMR measurements
contained*1mM peptide in 90% water=10% 2H2O (vol=vol)
at approximately pH 3. Spectra were recorded at 290K on a
Bruker ARX-600 spectrometer equipped with a shielded
gradient unit. Additional spectra were acquired at 310K for
hybrid 8, hybrid 11, and hybrid 15. Two-dimensional NMR
spectra were recorded as previously described (16). Chemical
shifts were referenced to internal 2,2-dimethyl-2-silapentane-
5-sulfonate.
Oxidative folding of cycloviolacin O1. Oxidative folding
was carried out on the linear cycloviolacin O1 assembled with
a thioester group and also on the base-treated linear chain
from which the thioester group was removed. The thioester
group was removed by incubating linear cycloviolacin O1 in
0.1M potassium hydroxide (pH 11.5) for 10min followed by
purification on an RP-HPLC column.
Oxidative folding and reductive unfolding of hybrid 15. Pu-
rified hybrid 15 containing the thioester linker (0.5mg=ml)
was cyclized, and the cysteine residues were maintained in a
reduced state by incubation in 0.1M ammonium bicarbonate
buffer (pH 8.5) containing sixfold excess Tris (carboxyethyl)
phosphine hydrochloride for 45min at 258C. For oxidative
folding, the purified reduced cyclic hybrid 15 was oxidized in
oxidation condition 6. Aliquots were taken out at various time
intervals, quenched with 0.4% TFA, and analyzed with ana-
lytic RP-HPLC. The major intermediate of hybrid 15 was
captured by quenchingwith 0.4% TFA after 5min of oxidative
folding. The native hybrid 15was obtained by quenchingwith
0.4% TFA after 24 h of oxidative folding. The intermediate and
the native hybrid 15 were purified on RP-HPLC and charac-
terized with ESI-MS and NMR. For reductive unfolding,
purified native hybrid 15 (0.5mg=ml) was reduced in am-
monium bicarbonate buffer (pH 8.5) containing 25mM di-
thiothreitol at 258C. Aliquots were taken out at various time
intervals, quenched with 0.4% TFA, and analyzed with ana-
lytic RP-HPLC.
Oxidative folding and reductive unfolding of kalata
B8. Native kalata B8 was isolated from the aerial parts of
Oldenlandia affinis plants by using a standard extraction pro-
cedure (16). The peptide (0.5mg=ml) was reduced in 300mM
DTT containing ammonium bicarbonate buffer (pH 8.5) for
24 h at 258C, purified on HPLC, and used for the oxidative
folding study. Oxidative folding was carried out in standard
oxidation condition 9, shown in Table 1. For reductive un-
folding, a purified native species (0.1mg=ml)was dissolved in
0.1M ammonium bicarbonate (pH 8.0) containing 50mM
DTT at 258C. Aliquots were removed at various time inter-
vals, quenched with 0.4% TFA, and analyzed with analytic
RP-HPLC.
Results
The main aim of the current study was to understand the
reasons for poor folding of bracelet cyclotides under condi-
tions in which Mo¨bius cyclotides fold readily. To this end, we
used a range of bracelet:Mo¨bius hybrids to unravel the factors
that influence the in vitro folding of cyclotides.
Cycloviolacin O1 is structurally well characterized and was
chosen as the prototypical bracelet cyclotide for the investiga-
tion. We analyzed the oxidative folding of this cyclotide under
a panel of standard oxidation conditions given in Table 1.
Typically, native cyclotides elute late on RP-HPLC as a result
of their surface-exposed patch of hydrophobic residues (17).
The native form can readily be confirmed by 1H-NMR analysis
as cyclotides display well-dispersed NMR signals. Misfolded
peptides usually givemultiple overlapping peaks onRP-HPLC
and do not have well-dispersed NMR signals.
In an initial series of experiments on the folding of cyclo-
violacin O1, only misfolded isomers were observed under the
panel of conditions tested. To determine whether the folding
could be improved if oxidation occurs before cyclization,
we also examined the folding of the linear chain. However,
the peptide still misfolded, indicating that even when di-
sulfide bond formation occurred before the constraints im-
posed by cyclization, it was not possible to obtain correctly
folded product (data not shown).
We then focussed on kalata B8, a natural hybrid between
Mo¨bius and bracelet subfamilies, to identify the ‘‘offender’’
loops responsible for the misfolding of bracelet cyclotides in
vitro. In kalata B8, loops 2 and 3 closely resemble Mo¨bius
sequences, and loop 5 resembles bracelet cyclotides (16), as
shown in Fig. 2. We found that kalata B8 readily folds into a
native conformation in vitro, as shown in Fig. 2, which led to
the proposal that loops 2 and 3 are likely to be the reason for
themisfolding in bracelet cyclotides. A comparison of bracelet
and Mo¨bius sequences indicates that the amino acid se-
quences in loops 2 and 3 differ most significantly between the
two subfamilies, supporting the proposal that bracelet loops 2
and 3 may have a major impact on folding. Thus, it was
proposed that correct folding in cycloviolacin O1may occur if
loops 2 and 3 are substituted with the counterpart Mo¨bius
sequences.
We therefore designed a suite of hybrid peptides contain-
ing different loop combinations from both subfamilies, as
shown in Fig. 3, with initial focus on loops 2 and 3. The
Mo¨bius cyclotide kalata B1 and bracelet cyclotide cyclovio-
lacin O1 were used as the representative members for each
cyclotide subfamily, as detailed structural data are available
for both peptides (40). Hybrid 1 involves replacement of loop
2 of the cycloviolacin O1 sequence with the kalata B1 loop 2











1 100% – – –
2 100% – 2mM –
3 100% – 2mM 0.4mM
4 75% 25% – –
5 75% 25% 2mM –
6 75% 25% 2mM 0.4mM
7 50% 50% – –
8 50% 50% 2mM –
9 50% 50% 2mM 0.4mM
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sequence. As indicated in Fig. 3, this peptidemisfolded in vitro,
indicating that engineering a Mo¨bius loop 2 into a bracelet
cyclotide is not sufficient to facilitate folding. Hybrid 2 is a
cycloviolacin O1 sequence with loop 3 replaced by the kalata
B1 loop 3 sequence. Loop 3 of the bracelet cyclotides is strik-
ingly different in size and sequence from that in Mo¨bius cy-
clotides. Unlike in themembers of theMo¨bius subfamily, loop
3 is helical in the bracelet subfamily and contains residues that
form part of the hydrophobic surface of cyclotides (40). Thus,
this region stands out as the most likely region to differentiate
the folding pathways of the two subfamilies. Surprisingly,
hybrid 2 also misfolded, indicating that the Mo¨bius loop 3 is
not sufficient to induce correct folding.
The results from the initial hybrid peptides led us to con-
sider the possibility that the residues that influence folding are
embedded in several loops across the sequence and not just
confined to a single loop. Thus, we designed hybrid 3, which
contains both loops 2 and 3 of cycloviolacin O1, replaced with
the corresponding kalata B1 sequences. However, misfolding
of this peptide demonstrated that this loop combination does
not facilitate correct folding of cycloviolacin O1. Accordingly,
we designed several peptides containing other loop combi-
nations. Hybrid 4, containing kalata B1 loops 2 and 5, as well
as hybrid 5, which contains kalata B1 loops 3 and 5, both
misfolded. Hybrid 6, which contains loops 2, 3, and 5 of kalata
B1, also misfolded, indicating that these three loops alone are
not sufficient to facilitate folding. However, when loop 6 was
also changed into a Mo¨bius sequence (Hybrid 7), the peptide
correctly folded (oxidation condition 8), indicating that loop 6
has a major impact on folding. A sharp late-eluting peak
characteristic of a well-folded peptide was observed on RP-
HPLC, as shown in Fig. 3, and was confirmed to contain
correctly folded peptide by 1H-NMR. Specifically, aH che-
mical shifts are extremely sensitive to structural changes and
indicated similarity of this hybrid to native kalata B1 (Fig. 4).
We chose not to modify loops 1 and 4 for any hybrids, as
these loops form part of the cystine knot and are tightly
conserved across the two cyclotide subfamilies. Thus, they
FIG. 2. Oxidative folding and reductive unfolding pro-
files of kalata B8. The sequence alignment of kalata B8 with
representative members from Mo¨bius and bracelet sub-
families shows that it is a natural hybrid of the two sub-
families; loops 2 and 3 resemble Mo¨bius sequences, and loop
5 resembles bracelet sequences, as highlighted in boxes. The
reductive unfolding of kalata B8 (left) depicts the unfolding
of the native to the reduced form without a characteristic
intermediate (i.e., an ‘‘all or none’’ unfolding mechanism).
Under standard oxidation condition 9, reduced kalata B8
readily folds to the native conformation (right).
FIG. 3. Sequence alignment of designed Mo¨bius-bracelet
hybrids and selected RP-HPLC profiles of hybrids. The
sequences of the synthetic hybrid peptides are shown along
with inset panels showing HPLC traces of typical folding
reactions. The designed hybrids contain a combination of
different loops from the two prototypical scaffolds. The se-
quences highlighted with ticks indicate correctly folded ana-
logues. (A) Hybrid 13 is a well-folded peptide (indicated by *)
formed in high yields. (B) Hybrid 6 shows the characteristic
pattern for a misfolded peptide consisting of several closely
eluting several broader peaks. (C) Hybrid 11 is a well-folded
peptide (indicated by *), eluting late after a mixture of mis-
folded isomers.
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were not expected to induce differential folding behavior.
This assumption is supported by the fact that hybrid 7 con-
tains bracelet loops 1 and 4, but still folds correctly, unlike
most bracelet cyclotides.
Hybrid 8, which contains kalata B1 loops 3 and 6, mis-
folded, but hybrid 9, which contains kalata B1 loops 2 and 6,
gave a prominent late-eluting peak on RP-HPLC (oxidation
condition 6) that was confirmed by NMR to contain the cor-
rectly folded material. As shown in Fig. 4, the aH chemical
shifts of hybrid 9 closely follow those of native kalata B1,
indicating that it maintains a native cyclotide conformation.
Overall, it became clear that the presence of certain residues
in Mo¨bius loops 2 and 6 synergistically induces correct fold-
ing. Further, as hybrid 9 contains bracelet loops 3 and 5, these
loops apparently do not cause cyclotides to misfold. These
findings for hybrid 9 are quite significant, as they eliminate
some of the key misconceptions on bracelet folding (i.e.,
the misfolding in bracelet cyclotides may be caused by either
the helical bracelet loop 3 or the lack of a cis-Pro in the bracelet
loop 5). The ability to translocate a bracelet loop 3 onto a
Mo¨bius scaffold without causing it to misfold suggests that
loop 3 is a highly permissive region for modification or bio-
active epitope insertion. Supporting inferences were made
from hybrid 10, designed by replacing loops 2, 3, and 6 of
cycloviolacin O1 with the corresponding kalata B1 sequences.
This peptide folded into a native-like conformation (oxidation
condition 8), indicating that the presence of bracelet loop 5
does not lead to misfolding. This is consistent with a previous
study on kalata B1 analogues that had cationic residues from a
bracelet counterpart substituted into loop 5 and correctly
folded cyclotide analogues were obtained (9).
The next step was to investigate whether specific residues
in loops 2 and 6 influence folding. Loop 2 of kalata B1 contains
the sequence VGGT, whereas the corresponding loop in cy-
cloviolacin O1 is VYIP. Hybrid 11, designed to contain the
VYGT sequence in loop 2, folded into a native conformation
(oxidation condition 1), confirming that the Tyr residue that
resides in loop 2 of cycloviolacin O1 is not responsible for
misfolding. However, the NMR peaks for the Tyr residue
were broadened at 290K, as were the amide protons of Cys5,
Val6, Try7, and Asn11. Additional spectra acquired at higher
temperatures (310K) allowed the observation of all spin sys-
tems, but the broadening behavior indicated that the loop 2
with the VYGT sequence is likely to be flexible. Interestingly,
when the sequence in loop 2 was altered to VYIT (hybrid 12),
the peptide misfolded, indicating that the Ile residue at the
third position of this loop is not compatible with folding
into the native conformation.
Next we aimed to identify the specific residues in loop 6
that cause misfolding. Comparison of loop 6 sequences across
kalata B1 and cycloviolacin O1 revealed that the sequences are
quite similar except for the Thr at the start and Val at the end
that are missing in cycloviolacin O1. Thus, we wanted to de-
termine whether these missing residues have an impact on
folding in the bracelet framework. Hybrid 13was designed by
modifying the hybrid 6 sequence with an extra Thr at the start
of loop 6. This small change resulted in a folded peptide
(oxidation condition 8), indicating that introducing a Thr
residue can facilitate folding. Hybrid 14 designed by intro-
ducing a Val at the end of loop 6 of hybrid 6, however, did not
fold correctly, indicating that the Val may not have an influ-
ence on folding.
To confirm our findings, we made hybrid 15, which is
basically the cycloviolacin O1 sequence with the replacement
of the Ile with Gly in loop 2 and the addition of a Thr at
the start of loop 6. Hybrid 15 readily folded into a native
FIG. 4. A comparison of
aH chemical shifts of folded
hybrid analogues and kalata
B1. The aH NMR chemical
shifts were derived from anal-
ysis of TOCSY and NOESY
spectra recorded at 600MHz,
290K. The sequence differences
for the hybrid from kalata B1
are highlighted below the
kalata B1 sequence. Hybrid 11
(triangle), hybrid 15 (vertical
line), hybrid 8 (cross), hybrid 10
(square), hybrid 7 (diamond),
kalata B1 (horizontal line),
hybrid 13 (circle). The gaps in
the chemical-shift profile result
from kalata B1 having fewer
residues in loop 3 than does
cycloviolacin O1.
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conformation by using oxidation condition 6, as shown in
Fig. 5, and the presence of the cystine knot topology was
confirmed from aH chemical shifts (Fig. 4). Thus, overall the
data show that loops 2 and 6 in native cycloviolacin O1 are
the primary cause of misfolding in bracelet cyclotides, and
by two changes to the sequence, an amino acid substitution
and an amino acid addition, the natively folded conforma-
tion can be rescued.
We also examined the reductive unfolding and oxidative
folding pathways of hybrid 15. In the reductive unfolding of
hybrid 15, no folding intermediates were seen, as shown in
Fig. 5. The peptidewas reducedwithin 10min in the reduction
buffer and resulted in a broad peak on RP-HPLC. The reduced
peak for hybrid 15 is significantly broader than that observed
for the reduced form of kalata B8, and such broadening on RP-
HPLC can indicate the presence of multiple conformations.
FIG. 5. Oxidative folding and reductive unfolding of hybrid 15. (A) In the reductive unfolding of hybrid 15, no folding
intermediates are present. (B) In the oxidative folding of hybrid 15, a major intermediate (MI) containing three nonnative
disulfide bonds is present. MI converts to the native (N) conformation in standard oxidation condition 6. The HPLC traces are
offset in the diagram for clarity.
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During oxidative folding of hybrid 15, a major intermediate
(MI) was present together with other minor intermediates, as
shown in Fig. 5. MI accumulated as the major species during
the initial 6 h of folding, andmass analysis indicated that it is a
three-disulfide isomer of hybrid 15. Over a 24-h time period,
MI converted to the native form.
To gain information on the structure and the disulfide
connectivity of MI, we compared the NMR secondary aH
chemical shifts of MI, native hybrid 15, and the major inter-
mediate present in the folding pathway of cycloviolacin O2
(1). Secondary shifts reflect the difference in shift of a given
residue in a peptide of interest from that of the same residue in
a random coil peptide, and in general, the larger the second-
ary shifts, the more structured the peptide. As is apparent
from Fig. 6, the secondary shifts for MI residues in loops 1 to 4
are generally smaller than in the native hybrid 15, suggesting
a less-well-defined structure in this region. Indeed, the aver-
age secondary shift in this region is <0.2 ppm, which makes
the region close to random coil. However, the secondary shifts
for loop 5 and 6 residues are very similar to those of the native
species, indicating a similar conformation in these loops.
Loops 5 and 6 of the prototypical bracelet cyclotide cyclo-
violacin O1 form a b-hairpin, which is a key element of its
secondary structure (40). Specifically, the b-hairpin is formed
by strand 1 (residues 19 to 21) and strand 2 (residues 24 to 26),
which are linked by a type I b-turn involving residues 21 to 24
(40). The similarity in the secondary shifts ofMI and the native
conformation of hybrid 15 in loops 5 and 6 suggests that the
b-hairpin motif is most likely intact in MI. The two most
significant differences in shifts between hybrid 15 and MI are
for the Cys residues preceding loops 5 and 6. Given the sim-
ilarity of all of the other shifts and hence the similar hairpin
conformation, the most likely explanation for the differences
in Cys secondary shifts is that they have a different (i.e.,
nonnative) disulfide connectivity in the intermediate com-
pared with the native hybrid 15 structure.
A characteristic three-disulfide isomer with nonnative dis-
ulfide bonds is present in the folding pathway of the bracelet
cyclotide cycloviolacin O2 (1). As shown in Fig. 6, a similar
pattern of secondary shifts is seen for MI and that intermediate
in all loops. In the cycloviolacin O2 folding intermediate, dis-
ulfide bonds are present between CysI and CysII, CysIII and
CysIV, and CysV and CysVI (1), and the same nonnative con-
nectivity is likely to be present in MI. Thus, overall, our data
suggest that the folding intermediate MI identified in the cur-
rent study, which is formed early in the folding pathway, has a
native-like hairpin structure but has nonnative disulfide bonds
and is relatively unstructured in the non-hairpin regions. It
appears that the b-hairpin structure is a crucial nucleation locus
for protein folding in bracelet cyclotides.
Discussion
In this study, we examined the in vitro folding of a series of
Mo¨bius:bracelet hybrid cyclotides and determined that two
specific loops play a significant role in the folding. Although
the Mo¨bius subfamily of cyclotides has previously been
shown to fold efficiently into the native conformation in vitro,
the bracelet cyclotides had until recently proven intractable
under a range of standard oxidation conditions. The hybrid
cyclotides made for this studywere assembled by using solid-
phase peptide synthesis with a thioester strategy for forming
the cyclic backbone. The foldingwas examinedwithRP-HPLC
and NMR spectroscopy. Characteristic features observed
when the cyclotides folded into their native conformations
included late-eluting peaks on HPLC and well-dispersed
amide signals in NMR spectra. Analysis of the folding yields
of the hybrids indicated that the complexity in the in vitro
FIG. 6. Comparison of the secondary aH
chemical shifts of the major intermediate
(MI), native hybrid 15, and the folding in-
termediate in cycloviolacin O2. (A) Com-
parison of native hybrid 15 (white), MI (black),
and the major intermediate in cycloviolacin
O2 (gray) (1); the peptide sequence alignment
contains hybrid 15 (top) and cycloviolacin O2
(bottom). (B) The structural features of hybrid
15. The two changes from cycloviolacin O1
made in hybrid 15 are highlighted on the
structure of cycloviolacin O1; an amino acid
substitution was made in loop 2 where the Ile
is highlighted, and an amino acid addition
was made to loop 6 at the site indicated by an
arrow.
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folding of the bracelet cyclotide cycloviolacin O1 is sequence
dependent and is hindered mainly by residues in backbone
loops 2 and 6. By substituting a single residue in loop 2, and
with the addition of an extra residue in loop 6 to resemble the
prototypical Mo¨bius cyclotide kalata B1, it was possible to
obtain the native fold for several cyclotide hybrids by using
simple in vitro folding conditions. The findings from this work
are significant because understanding the mechanistic details
of the in vitro folding in cyclotides is potentially invaluable for
protein-engineering applications that use cyclotide scaffolds
for the stabilization of bioactive sequences.
We determined that replacement of either loop 2 or loop 6
of cycloviolacin O1 with corresponding kalata sequences, one
at a time, does not result in a natively folded conformation.
Thus, the contribution of these loops individually to the sta-
bility of the native fold is not sufficient to induce correct
folding. Correct folding in the hybrids is not promoted unless
both loops 2 and 6 are replaced simultaneously with Mo¨bius-
like sequences, suggesting the possibility of a synergistic in-
teraction between residues in these loops at some point on the
folding pathway or in the final product. The specific residues
favorable for folding in the hybrid are a Gly in loop 2 and a
Thr in loop 6. The structure in Fig. 6 shows that these residues
are remotely located from each other (40), thus excluding their
synergistic interaction in the final fold.
Given the lack of a possible synergistic interaction in the
final fold, the observed folding data were then examined for
fit to other folding models that would implicate these resi-
dues, the first being that they play a cumulative role in sta-
bilizing the final structure, thus driving folding on a
thermodynamic basis; and the second, that they have syner-
gistic interactions early in the folding process when they
might be closer to one another before the final fold takes
shape. Structural analysis of kalata B1 shows that Gly8 in loop
2 has a positive j angle and is involved in a type I b-turn (40).
In native cycloviolacin O1, the Ile8 that occupies this position
has a negative j angle, even though it is also involved in a
type I b-turn. The differences in j angles suggest that differ-
ences exist in the orientation of these residues and hence dif-
ferent local interactions established among neighboring
residues. Thus, it is possible that the Gly8 in the ‘‘foldable’’
hybrids induces a thermodynamically favorable turn in loop
2. In addition, introducing a hydroxyl-bearing Thr may fa-
cilitate the formation of hydrogen bonds across the b-hairpin,
similar to those observed in kalata B1 (40), which may pro-
mote correct folding. Further amino acid replacements, such
as substitution of the Thr in loop 6 with a non–hydroxyl
containing residue, may provide additional information re-
garding the role of this residue in folding. However, it appears
that the combination of the Gly in loop 2 and the Thr in loop 6
stabilizing factors is the minimal requirement to rescue the
otherwise unfavorable in vitro folding of bracelet cyclotides.
To examine the possibility that these residues alternatively
play a role earlier in the folding pathway, perhaps through
mutual synergistic interactions, it was necessary to probe the
structure of the nonnative three-disulfide intermediate that
accumulates in the folding of hybrid 15. An intermediate with
a similar secondary structure was recently reported in the
folding of cycloviolacin O2 (1). Interestingly the cycloviolacin
O2 intermediate does not readily convert to the native form
under standard oxidation conditions and requires very spe-
cific folding conditions to convert to the native form. By
contrast, the intermediate present in hybrid 15 readily con-
verts to the native form under standard oxidation conditions.
It appears that introducing the Gly and Thr changes in loop 2
and 6 modulates the stability of the folding intermediate,
enabling it to undergo the disulfide shuffling necessary to
convert to the native form.
A chemical-shift analysis of MI and comparison with the
cycloviolacin O2 intermediate indicates that the b-hairpin is
present in MI and is most likely stabilized by a CysV-CysVI
disulfide bond. Based on the time course of the folding of
hybrid 15, MI appears early in the folding, and thus, the
b-hairpin most likely serves as a nucleation site for folding.
Furthermore, the early appearance of the hairpin motif, while
the rest of the intermediate is relatively unstructured, suggests
that the potential hydrogen-bonding interactions of the Thr
residue also assist in stabilizing the formation of the hairpin.
Because formation of the hairpin effectively precludes a close
synergistic interaction of the key Thr and Gly residues, each
probably contributes separately but cumulatively to stabili-
zation of the intermediate Thr by stabilizing the nucleating
b-hairpin and Gly by assisting in formation of the turn in loop
2 that forms later.
Overall, the folding mechanism developed here first in-
volves formation of a b-hairpin involving loops 5 and 6 that
forms early to produce a readily detectable and long-lived
intermediate. The intermediate has nonnative disulfide
bonds, most likely formed between successive pairs of Cys
residues. This suggestion is consistent with an initial kineti-
cally driven formation of disulfide bonds between Cys resi-
dues that are closest together in the sequence. The resultant
intermediate converts to the native form via the formation of a
turn in loop 2 and disulfide reshuffling.
It is interesting to note that the residues that were deter-
mined to be important for in vitro folding are present in the
sequence of the ‘‘natural chimera,’’ kalata B8 (16). Specifically,
a Gly residue at the third position in loop 2 and a Thr at the
start of loop 6 are present. The fact that kalata B8 folds into a
native conformation in vitro further confirms that these resi-
dues in loops 2 and 6 have a prominent role in folding.
As the primary amino acid sequence in a protein is thought
to dictate its folding mechanism and final topology (3, 19), the
question arises as to whether the sequence hypervariability
observed in the cyclotides is associatedwith a large number of
folding mechanisms. Alternatively, does the partial sequence
conservation observed within each cyclotide subfamily mean
that the conserved residues dictate a common mechanism for
the subfamily? Detailed oxidative folding pathways have
now been determined for a representative member from each
of the three cyclotide subfamilies (1, 6, 15). Mo¨bius and
trypsin-inhibitor cyclotides have different folding pathways,
despite having a common two-disulfide intermediate con-
taining native-like disulfide bonds (6, 15). In Mo¨bius cyclo-
tides, this intermediate, despite having two native disulfide
bonds, is not the direct precursor of the native form and re-
quires disulfide reshuffling to convert into the native form
(15). The inability to isolate the direct precursor of the native
form in the refolding of kalata B1 indicates that it is likely to be
a transient intermediate. The intermediate seen for the pro-
totypical trypsin inhibitor cyclotide MCoTI-II directly con-
verts to the native form and appears to be an on-pathway
intermediate. As already noted, a recent study that examined
the folding bracelet cyclotide, cycloviolacin O2, identified a
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three-disulfide intermediate with nonnative bonds as the
major species present during folding (1). Other one-disulfide
and three-disulfide intermediates were also present as minor
products during folding, but no two-disulfide intermediates
were seen. Cycloviolacin O2 was also shown not to fold cor-
rectly under conditions generally used for kalata B1. Under
the folding conditions used in this study, we also observed a
suite of misfolded isomers for cycloviolacin O1. Collectively,
these results suggest that folding of bracelet cyclotides occurs
via a pathway that is different from both Mo¨bius and trypsin
inhibitor subfamilies, at least in vitro.
The folding situation in vivo is likely to be more complex
still, likely involving folding auxiliaries. For example, a pro-
tein disulfide isomerase was recently isolated from the
cyclotide-producing plant Oldenlandia affinis and shown to
facilitate cyclotide folding (26). As well as delineating which
residues are important for facilitating folding, the findings
from the current study also identified regions within the cy-
clotide scaffold that are not important for folding and are thus
permissive to mutations. This knowledge will facilitate the
use of a range of cyclotides, including bracelet cyclotides, as
grafting scaffolds in protein-engineering applications.
In summary, the current study has enhanced the informa-
tion known regarding the folding of cyclotides and has pro-
vided a mechanistic insight into cyclotide folding, identifying
the specific structural elements that influence correct folding,
and demonstrated that they are localized within two inter-
cysteine loops. More generally, the study complements other
recent studies on the folding of a wide range of disulfide-rich
peptides and proteins (2).
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